28 results
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
from achieving or maintaining market acceptance of the particular product candidate, if approved.
Tenet faces significant competition in an environment
DEFM14A
ELYM
Eliem Therapeutics Inc
4 Jun 24
Proxy related to merger
8:00am
relevant.
RISK FACTORS
Post-Closing Eliem will be faced with a market environment that cannot be predicted and that involves significant risks, many … faces significant competition in an environment of rapid technological change, and there is a possibility that its competitors may achieve regulatory
PREM14A
ELYM
Eliem Therapeutics Inc
17 May 24
Preliminary proxy related to merger
4:36pm
environment that cannot be predicted and that involves significant risks, many of which will be beyond its control. In addition to the other information … of the particular product candidate, if approved.
Tenet faces significant competition in an environment of rapid technological change, and there is a possibility
DEFA14A
ELYM
Eliem Therapeutics Inc
11 Apr 24
Additional proxy soliciting materials
8:10am
arising from the release or threatened release of any Materials of Environmental Concern into the environment.
(c) The Company is not a party … ) of the assets of any business or portion thereof.
54-
“Environmental Law” means any Law relating to the environment, occupational health and safety, or exposure
8-K
EX-2.1
l3kcfr
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.4
1p34enp0
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
10-K
q0f vo3m1
7 Mar 22
Annual report
4:03pm
10-Q
kgbiaa0
13 Sep 21
Quarterly report
4:01pm
424B4
xgv7y
11 Aug 21
Prospectus supplement with pricing info
5:05pm